论文部分内容阅读
目的：采用对比法分析瑞舒伐他汀和阿托伐他汀对冠心病患者在非调脂、调脂方面及动脉粥样硬化逆转和安全性方面的疗效。方法选取2010年10月至2013年4月我院进行冠状动脉造影并证实为冠心病的患者160例，对其实施常规治疗。采取随机抽签分组的方式分为两组，治疗组口服瑞舒伐他汀片，对照组口服阿托伐他汀，疗程均为1年。对所有患者在治疗前、治疗后6、12个月的疗效、安全性进行比较。结果疗程结束后，组间比较发现治疗组各项均优于对照组，且组内比较也具有统计学意义。结论瑞舒伐他汀与阿托伐他汀两种药物均对动脉粥样硬化进程具有良好的逆转或延迟作用，能有效降低冠心病患者Hcy和血hs-CRP水平，改善患者血脂状况，但瑞舒伐他汀较阿托伐他汀的效果更加显著。“,”Objective With the method of comparison research and analysis of rosuvastatin and atorvastatin on curative effect of patients with coronary heart disease in non lipid, lipid and atherosclerosis reversal and security. Methods From 2010 October to 2013 April in our hospital for coronary angiography and confirmed 160 cases of coronary heart disease patients,the conventional treatment.Take the random way were divided into two groups, treatment group oral rosuvastatin tablets;the control group oral atorvastatin,treatment for 1 years.Al of the patients before and after the treatment,6,12 months curative effect,safety of comparison.Results After treatment,comparison between groups treatment group were better than the control group,and there was also significant within group comparison.Conclusion Rosuvastatin and atorvastatin two drugs have good reversal of atherosclerosis or delay action,can effectively reduce Hcy in patients with coronary heart disease and blood hs-CRP levels,improve blood lipid status of the patients,but rosuvastatin compared with atorvastatin more remarkable effect.